The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
Publications
Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
Journal of hematology & oncology. 2010;3:12
Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction.
Investigational new drugs. 2010;28(2):185-6
Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
JOP : Journal of the pancreas. 2008;9(2):197-202
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
European journal of cancer (Oxford, England : 1990). 2005;41(15):2262-7
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Anti-cancer drugs. 2004;15(6):605-7
Hypersensitivity reactions related to oxaliplatin (OHP).
British journal of cancer. 2003;89(3):477-81